Canaccord analyst Edward Nash initiated coverage of Viking Therapeutics (VKTX) with a Buy rating and $106 price target The firm views Viking as a leader in the obesity drug development space. It expects a readout from the company’s two Phase 3 trials in 2027 and mid-2028, respectively. Viking also reported “strong” efficacy Phase 2 data in August from the oral version of VK2735, the analyst tells investors in a research note. Canaccord believes the drug can differentiate on “multiple fronts.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics initiated with a Buy at Canaccord
- Viking Therapeutics’ VK2735: A Promising Phase 3 Study for Weight Management
- Viking Therapeutics’ VK2735 Study: A Potential Game-Changer for Weight Management in Type 2 Diabetes
- Viking Therapeutics price target lowered to $75 from $80 at JPMorgan
- Viking Therapeutics Navigates Regulatory Risks Amid U.S. Policy Shifts